Riboxin-Darnitsa (inosine) ampoules 20 mg/ml 5 ml. №10


Manufacturer: Ukraine

Complex treatment of ischemic heart disease (state after myocardial infarction, angina), heart rhythm disorders, intoxication with cardiac glycosides, treatment of cardiomyopathies of different Genesis , myocardiodystrophy (against the background of heavy physical exertion, infectious and endocrine Genesis), myocarditis; liver diseases (hepatitis, cirrhosis, fatty liver dystrophy); urocoproporphyria.


Riboxin-Darnitsa (inosine) ampoules 20 mg/ml 5 ml. №10


active ingredient: inosine;

1 ml of solution contains riboxin (inosine) 20 mg;

excipients: sodium hydroxide, water for injection.

Dosage form


Basic physical and chemical properties: transparent colorless liquid.

Pharmacological group

Cardiac drugs.
ATX code C01E B.

Pharmacological properties

Riboxin belongs to the group of cardiological agents.
Due to its properties, the drug improves metabolic processes in the myocardium, increases the strength of heart contractions and the activity of a number of enzymes of the Krebs cycle, promotes more complete relaxation of the myocardium in diastole. Improves blood supply to tissues and coronary blood supply, activates tissue regeneration (in particular myocardium, intestinal mucosa and stomach).

Indications for use

Riboxin-Darnitsa is used as part of complex treatment for:

  • ischemic heart disease (heart rhythm disturbances, angina pectoris);
  • glycosidic intoxication;
  • cardiomyopathies of various origins;
  • myocarditis;
  • peptic ulcer of the stomach and duodenum;
  • liver diseases (chronic and acute hepatitis, drug and alcoholic liver damage, liver cirrhosis and fatty liver disease);
  • open-angle form of glaucoma.


The drug Riboxin-Darnitsa is contraindicated for use in the presence of diseases such as gout, hyperuricemia. Also, the drug is not used by persons with increased susceptibility to the components of the drug and in childhood.

Pregnancy and breastfeeding period

The use of the drug Riboxin during pregnancy and lactation has not been studied.

Mode of application

Riboxin-Darnitsa is intended for intravenous use.

The drug is used by adults in a jet or drip (slowly) at a rate of 40-60 drops per minute.

With intravenous drip, the drug is diluted in 5% glucose solution or 0.9% sodium chloride solution (up to 250 ml). At the beginning of treatment, 200 mg (10 ml of a 2% solution) is administered 1 time per day, subsequently, with good tolerance, the dose can be increased to 400 mg (20 ml of a 2% solution) 1-2 times a day. The course of treatment is determined individually, on average – 10-15 days.

Jet administration is possible in case of acute cardiac arrhythmias in a single dose of 200–400 mg (10–20 ml of a 2% solution).


The drug is not used in children due to lack of data on the safety of use.


An overdose of Riboxin-Darnitsa is accompanied by the following symptoms: allergic reactions, exacerbation of gout, tachycardia, increased manifestations of adverse reactions. In case of drug intoxication, symptomatic treatment is used.

Adverse reactions

The use of the drug Riboxin-Darnitsa very rarely causes side effects, but sometimes it is possible: itching, rash, skin flushing, an increase in the concentration of uric acid in the blood and tachycardia. With prolonged use or administration in high doses, exacerbation of gout may occur.